Ark Therapeutics and PsiOxus Therapeutics Ltd have announced that their partnership has successfully achieved its first milestone, by the timely manufacture of PsiOxus’s ColoAd1 oncoloytic adenoviral product.
The material was manufactured at Ark’s facility in Kuopio, Finland, using Ark’s proprietary suspension based single use process (“ATOSUS”), which was able to achieve the required product quality and demonstrate capability to exceed target process yields. ColoAd1 is under development by PsiOxus for the treatment of colorectal cancer.
To hear more about the manufacturing activities being undertaken by Ark Therapeutics and to discover the headway they are making into optimising the process, you need to be at the World Gene Therapy Congress, where Robert Shaw, the Technical Director at Ark will be discussing standardised scalable processes.
The World Gene Therapy Congress will be taking place on the 22-23 May 2012 in London and will be happening alongside the World Stem Cell and Regenerative Medicine Congress!
To read the full article click here